On October 9, Twist Bioscience Corp rose 5.23% overnight, trading at $159.04/share, with turnover of $215.33 million.

The move followed Jefferies initiating coverage on the stock with a Hold rating and a $150 price target. While the target is close to recent trading prices and offers limited upside, it helped ease short-term valuation-related selling pressure that had weighed on the stock. The previous day, the shares fell 5.63% amid broad weakness in the biotechnology sector and widening valuation debates around the synthetic DNA space.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products, serving applications in therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and academic research.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)